2225 related articles for article (PubMed ID: 18775388)
1. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
2. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
[TBL] [Abstract][Full Text] [Related]
3. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
4. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease.
Akazawa M; Hayflinger DC; Stanford RH; Blanchette CM
Am J Manag Care; 2008 Jul; 14(7):438-48. PubMed ID: 18611095
[TBL] [Abstract][Full Text] [Related]
5. Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy.
Dalal AA; Shah M; D'Souza AO; Crater GD
Respir Med; 2012 Jun; 106(6):829-37. PubMed ID: 22425138
[TBL] [Abstract][Full Text] [Related]
6. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD.
Dalal AA; Candrilli SD; Davis KL
Manag Care; 2011 Aug; 20(8):46-50, 53-5. PubMed ID: 21887993
[TBL] [Abstract][Full Text] [Related]
7. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
Blais L; Forget A; Ramachandran S
Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
[TBL] [Abstract][Full Text] [Related]
8. Effect of combination fluticasone propionate and salmeterol or inhaled corticosteroids on asthma-related outcomes in a Medicare-eligible population.
Stanford RH; Blanchette CM; Roberts MH; Petersen H; Fuhlbrigge AL
Am J Geriatr Pharmacother; 2012 Dec; 10(6):343-51. PubMed ID: 23083688
[TBL] [Abstract][Full Text] [Related]
9. Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies.
Delea TE; Hagiwara M; Dalal AA; Stanford RH; Blanchette CM
Curr Med Res Opin; 2009 Jan; 25(1):1-13. PubMed ID: 19210134
[TBL] [Abstract][Full Text] [Related]
10. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
Delea TE; Hagiwara M; Stanford RH; Stempel DA
Clin Ther; 2008 Mar; 30(3):560-71. PubMed ID: 18405796
[TBL] [Abstract][Full Text] [Related]
11. Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching.
Akazawa M; Biddle AK; Stearns SC
Clin Ther; 2008; 30 Spec No():1003-16. PubMed ID: 18640475
[TBL] [Abstract][Full Text] [Related]
12. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease.
Dalal AA; Roberts MH; Petersen HV; Blanchette CM; Mapel DW
Int J Chron Obstruct Pulmon Dis; 2010 Dec; 6():13-22. PubMed ID: 21311689
[TBL] [Abstract][Full Text] [Related]
13. Hospital and emergency department utilization associated with treatment for chronic obstructive pulmonary disease in a managed-care Medicare population.
Simoni-Wastila L; Yang HW; Blanchette CM; Zhao L; Qian J; Dalal AA
Curr Med Res Opin; 2009 Nov; 25(11):2729-35. PubMed ID: 19778165
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.
Roberts M; Mapel D; Petersen H; Blanchette C; Ramachandran S
J Med Econ; 2011; 14(6):769-76. PubMed ID: 21942463
[TBL] [Abstract][Full Text] [Related]
15. Clinical and economic outcomes in an observational study of COPD maintenance therapies: multivariable regression versus propensity score matching.
Roberts MH; Dalal AA
Int J Chron Obstruct Pulmon Dis; 2012; 7():221-33. PubMed ID: 22500122
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
Earnshaw SR; Wilson MR; Dalal AA; Chambers MG; Jhingran P; Stanford R; Mapel DW
Respir Med; 2009 Jan; 103(1):12-21. PubMed ID: 19010652
[TBL] [Abstract][Full Text] [Related]
17. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
[TBL] [Abstract][Full Text] [Related]
18. Mortality risk in patients receiving drug regimens with theophylline for chronic obstructive pulmonary disease.
Lee TA; Schumock GT; Bartle B; Pickard AS
Pharmacotherapy; 2009 Sep; 29(9):1039-53. PubMed ID: 19698009
[TBL] [Abstract][Full Text] [Related]
19. COPD-related healthcare utilization and costs after discharge from a hospitalization or emergency department visit on a regimen of fluticasone propionate-salmeterol combination versus other maintenance therapies.
Dalal AA; Shah M; D'Souza AO; Mapel DW
Am J Manag Care; 2011 Mar; 17(3):e55-65. PubMed ID: 21504260
[TBL] [Abstract][Full Text] [Related]
20. Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 μg/salmeterol 50 μg combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD.
Dalal AA; Petersen H; Simoni-Wastila L; Blanchette CM
J Med Econ; 2009; 12(4):339-47. PubMed ID: 19827993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]